Table 2.
Baseline Characteristics for the Overall Cohort Stratified According to Rs17216529 (n=827) *
| Baseline Characteristics | All (n=827) | hc of Major Allele (n=698) | Heterozygotes (n=127) | hc of Minor Allele (n=2) | p |
|---|---|---|---|---|---|
| Age (mean±SD) | 69 (±12) | 68 (±12) | 69 (±12) | 80 (±4) | 0.369 |
| No. of males | 586 (71%) | 498 (71%) | 86 (68%) | 2 (100%) | 0.444 |
| Cardiovascular risk factors | |||||
| Arterial hypertension | 689 (83%) | 579 (83%) | 108 (85%) | 2 (100%) | 0.367 |
| Hyperlipidemia | 480 (58%) | 405 (58%) | 75 (59%) | 0 (0%) | 0.199 |
| Diabetes mellitus type 2 | 271 (33%) | 233 (33%) | 37 (29%) | 1 (50%) | 0.674 |
| Smoking | 335 (41%) | 285 (41%) | 49 (39%) | 1 (50%) | 0.938 |
| Clinical factors | |||||
| Left ventricular ejection fraction [%] (mean±SD) | 51 (±11) | 51 (±11) | 51 (±10) | 38 (±4) | 0.194 |
| Creatinine [mg/dl] (mean±SD) | 1.0 (±0.6) | 1.0 (±0.6) | 1.1 (±0.5) | 1.6 (±1.0) | 0.370 |
| Medication on admission | |||||
| Acetylsalicylic acid | 459 (56%) | 378 (54%) | 79 (62%) | 2 (100%) | 0.111 |
| Clopidogrel | 103 (12%) | 82 (12%) | 20 (16%) | 1 (50%) | 0.128 |
| Prasugrel | 16 (2%) | 15 (2%) | 1 (1%) | 0 (0%) | 0.578 |
| Ticagrelor | 37 (4%) | 33 (5%) | 4 (3%) | 0 (0%) | 0.695 |
| Oral anticoagulation | 69 (8%) | 61 (9%) | 8 (6%) | 0 (0%) | 0.587 |
| ACE-inhibitors | 354 (43%) | 296 (42%) | 57 (45%) | 1 (50%) | 0.885 |
| Angiotensin-II-receptor antagonists | 150 (18%) | 126 (18%) | 24 (19%) | 0 (0%) | 0.785 |
| Ca-channel-blocker | 167 (20%) | 136 (19%) | 31 (24%) | 0 (0%) | 0.363 |
| Beta blockers | 470 (57%) | 388 (56%) | 80 (63%) | 2 (100%) | 0.161 |
| Statins | 395 (48%) | 332 (48%) | 62 (49%) | 1 (50%) | 0.981 |
| Reason of admission | |||||
| ACS | 407 (49%) | 349 (50%) | 56 (44%) | 2 (100%) | 0.168 |
| Stable CAD | 420 (51%) | 349 (50%) | 71 (56%) | 0 (0%) | 0.168 |
Note: *6 missing values.